Management of gastric cancer in Asia: resource-stratified guidelines
Top Cited Papers
- 1 November 2013
- journal article
- practice guideline
- Published by Elsevier BV in The Lancet Oncology
- Vol. 14 (12), e535-e547
- https://doi.org/10.1016/s1470-2045(13)70436-4
Abstract
No abstract availableKeywords
This publication has 76 references indexed in Scilit:
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trialThe Lancet Oncology, 2013
- A new approach for elimination of gastric cancer deaths in JapanInternational Journal of Cancer, 2012
- Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA studyGastric Cancer, 2012
- Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus ReportGut, 2012
- Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trialBritish Journal of Cancer, 2011
- Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)Gastric Cancer, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trialThe Lancet, 2008
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerThe New England Journal of Medicine, 2008